117 related articles for article (PubMed ID: 18695678)
1. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition.
Shiono M; Kobayashi T; Takahashi R; Sun G; Abe M; Zhang D; Wang L; Piao X; Takagi Y; Mineki R; Taka H; Tada N; Sonobe S; Momose S; Ueda M; Hino O
Oncogene; 2008 Nov; 27(52):6690-7. PubMed ID: 18695678
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
4. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
5. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
6. N-terminal hamartin-binding and C-terminal GAP domain of tuberin can separate in vivo.
Momose S; Kobayashi T; Tada N; Itoyama S; Hino O
Biochem Biophys Res Commun; 2007 May; 356(3):693-8. PubMed ID: 17379185
[TBL] [Abstract][Full Text] [Related]
7. Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis.
Adachi H; Majima S; Kon S; Kobayashi T; Kajino K; Mitani H; Hirayama Y; Shiina H; Igawa M; Hino O
Oncogene; 2004 Apr; 23(19):3495-500. PubMed ID: 14990989
[TBL] [Abstract][Full Text] [Related]
8. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex 2 loss-of-function mutation regulates reactive oxygen species production through Rac1 activation.
Suzuki T; Das SK; Inoue H; Kazami M; Hino O; Kobayashi T; Yeung RS; Kobayashi K; Tadokoro T; Yamamoto Y
Biochem Biophys Res Commun; 2008 Mar; 368(1):132-7. PubMed ID: 18230340
[TBL] [Abstract][Full Text] [Related]
10. Tuberin activates the proapoptotic molecule BAD.
Freilinger A; Rosner M; Krupitza G; Nishino M; Lubec G; Korsmeyer SJ; Hengstschläger M
Oncogene; 2006 Oct; 25(49):6467-79. PubMed ID: 16702951
[TBL] [Abstract][Full Text] [Related]
11. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles.
Plank TL; Yeung RS; Henske EP
Cancer Res; 1998 Nov; 58(21):4766-70. PubMed ID: 9809973
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
13. Tuberin nuclear localization can be regulated by phosphorylation of its carboxyl terminus.
York B; Lou D; Noonan DJ
Mol Cancer Res; 2006 Nov; 4(11):885-97. PubMed ID: 17114346
[TBL] [Abstract][Full Text] [Related]
14. Akt regulates nuclear/cytoplasmic localization of tuberin.
Rosner M; Freilinger A; Hengstschläger M
Oncogene; 2007 Jan; 26(4):521-31. PubMed ID: 16862180
[TBL] [Abstract][Full Text] [Related]
15. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.
Rosner M; Hanneder M; Siegel N; Valli A; Hengstschläger M
Mutat Res; 2008; 658(3):234-46. PubMed ID: 18291711
[TBL] [Abstract][Full Text] [Related]
16. Regulation of folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway.
Piao X; Kobayashi T; Wang L; Shiono M; Takagi Y; Sun G; Abe M; Hagiwara Y; Zhang D; Okimoto K; Kouchi M; Matsumoto I; Hino O
Biochem Biophys Res Commun; 2009 Nov; 389(1):16-21. PubMed ID: 19695222
[TBL] [Abstract][Full Text] [Related]
17. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.
Benvenuto G; Li S; Brown SJ; Braverman R; Vass WC; Cheadle JP; Halley DJ; Sampson JR; Wienecke R; DeClue JE
Oncogene; 2000 Dec; 19(54):6306-16. PubMed ID: 11175345
[TBL] [Abstract][Full Text] [Related]
18. The transcriptional profile of the kidney in Tsc2 heterozygous mutant Long Evans (Eker) rats compared to wild-type.
Sen B; Wolf DC; Hester SD
Mutat Res; 2004 May; 549(1-2):213-24. PubMed ID: 15120972
[TBL] [Abstract][Full Text] [Related]
19. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
[TBL] [Abstract][Full Text] [Related]
20. Tuberin, p27 and mTOR in different cells.
Burgstaller S; Rosner M; Lindengrün C; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2009 Feb; 36(2):297-302. PubMed ID: 18386114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
